research 706 Predictive modeling of patient response to JAK/STAT inhibitors and dynamic patient-matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
Search
for
Sort by
Research
480-510 / 1000+ results 
research IMMUNOLOGICAL AND SOME BIOLOGICAL BIOMARKERS INVESTIGATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
No single biomarker is reliable enough for diagnosing and assessing SLE.
research Abstracts
Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
research Granzyme B in Autoimmune Skin Disease
Granzyme B is important in autoimmune skin diseases and could be a new treatment target.
research 438 Laminin-511 is a new player in the development of psoriasis and controlled via cannabinoid receptor type 1
Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.
research An Unusual Presentation of Mucous Membrane Pemphigoid
Treatment with prednisolone and dapsone stopped new blisters and partially healed previous ones.
research 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
research JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
research 1114 Study of long-term (15-day) imiquimod treatment and drug intervention in localized psoriasiform dermatitis model
Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.
research Exploring differential gene expression and biomarker potential in systemic lupus erythematosus: a retrospective study
FCER1A and RGS1 may help diagnose and treat systemic lupus erythematosus.
research Śródskórne iniekcje acetonidu triamcynolonu w leczeniu Zespołu Grahama-Little’a — opis przypadku
Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.
research 569 The patient perspective on psoriasis disease remission
Psoriasis patients are willing to pay less than the cost of biologic treatments for remission and don't expect complete or long-term symptom clearance.
research S100A4/Nonmuscle Myosin IIA/p53 Axis Contributes to Aggressive Features in Ovarian High-Grade Serous Carcinoma
S100A4 promotes aggressive ovarian cancer and is a potential treatment target.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Successful treatment of refractory alopecia universalis with infliximab: First case report in Sri Lanka
Infliximab successfully treated a severe hair loss case in Sri Lanka.
research Alopecia Universalis: an extremely rare but probable adverse effect of adalimumab
Adalimumab can cause complete hair loss in rare cases.
research 0475 High-dose UVA-1 therapy improves patient-reported outcomes and clinical scores in patients with sclerosing skin disease
High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
research Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus
About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.
research 050 Evaluation of 3 month data for the use of erenumab for chronic migraine in Glasgow
Erenumab significantly reduced migraine days or severity in most patients after 3 months.
research ALOPECIA UNIVERSALIS TREATED WITH ORAL CYCLOSPORINE A AND PREDNISOLONE: IMMUNOLOGIC STUDIES
Oral cyclosporine A and prednisolone effectively improved alopecia universalis without side effects.
research 3D spheroid culture synchronizes heterogeneous MSCs into an immunomodulatory phenotype with enhanced anti-inflammatory effects
3D spheroid culture makes stem cells better at reducing inflammation.
research Alefacept for Severe Alopecia Areata
Alefacept does not effectively treat severe alopecia areata.
research Generation of Pax1/PAX1-Specific Monoclonal Antibodies
Researchers created specific antibodies that detect a protein important in development and various conditions, and can be used for research and diagnosis.
research A clinical study of pemphigus vulgaris and its variants, evaluation of safety and efficacy of glucocorticoids versus immunosuppressants at tertiary care hospital: a study of 75 cases
Combining glucocorticoids with immunosuppressants like cyclophosphamide improves remission and reduces relapse in pemphigus patients.
research Inhibition of Established Tuberculin Hypersensitivity by Methptrexate,
Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.
research Dupilumab Induced Hair Regrowth in Alopecia Totalis
Dupilumab may help regrow hair in people with severe alopecia.
research ZASTOSOWANIE TERAPII CAR-T W ONKOHEMATOLOGII DZIECIĘCEJ
CAR-T therapy offers hope for children with hard-to-treat blood cancers.
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study
The combination therapy is effective and well-tolerated for treating esophageal cancer.
research AP-1 and TGFß cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma
AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.